EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 346 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ACS’s Updated Cervical Cancer Screening Guidelines Explained September 18, 2020 Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... February 21, 2024 Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... December 18, 2019 Spring Budget 2023: What does it mean for the mission to... March 15, 2023 Load more HOT NEWS TRACERx: Using blood tests to track lung cancer Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... Marine Runs Five Marathons in Five Days to Help Fund Sister’s...
